- Report
- October 2025
- 193 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- October 2025
- 180 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- August 2025
- 196 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- August 2025
- 189 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- August 2025
- 197 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- August 2025
- 186 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- August 2025
- 185 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- August 2025
- 199 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- August 2025
- 195 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- August 2025
- 199 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- August 2025
- 194 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- September 2025
- 185 Pages
Global
From €3969EUR$4,500USD£3,487GBP
- Report
- August 2025
- 180 Pages
Global
From €3969EUR$4,500USD£3,487GBP
- Report
- December 2025
- 369 Pages
Global
From €5160EUR$5,850USD£4,533GBP
- Report
- December 2025
- 377 Pages
Global
From €5160EUR$5,850USD£4,533GBP
- Report
- December 2025
- 380 Pages
Global
From €5160EUR$5,850USD£4,533GBP
- Report
- December 2025
- 484 Pages
Global
From €5160EUR$5,850USD£4,533GBP
- Report
- December 2025
- 553 Pages
Global
From €5160EUR$5,850USD£4,533GBP
- Report
- December 2025
- 565 Pages
Global
From €5160EUR$5,850USD£4,533GBP
- Report
- December 2025
- 676 Pages
Global
From €5160EUR$5,850USD£4,533GBP

Continuous bioprocessing is a biotechnology-based approach to the production of biopharmaceuticals, such as vaccines, monoclonal antibodies, and recombinant proteins. It involves the use of continuous manufacturing techniques, such as continuous cell culture, continuous chromatography, and continuous purification, to produce biopharmaceuticals in a more efficient and cost-effective manner than traditional batch-based processes. This approach also allows for greater control over the production process, resulting in higher quality products.
Continuous bioprocessing has become increasingly popular in recent years, as it offers a number of advantages over traditional batch-based processes. These include improved process control, increased product yield, reduced production costs, and shorter production times.
Some companies in the continuous bioprocessing market include Merck KGaA, Novartis, Pfizer, Sanofi, and Lonza. Show Less Read more